Literature DB >> 21178339

Distribution of dexamethasone and preservation of inner ear function following intratympanic delivery of a gel-based formulation.

Alec N Salt1, Jared Hartsock, Stefan Plontke, Carl LeBel, Fabrice Piu.   

Abstract

Intratympanic (IT) delivery of drugs to the ear is increasingly used for both clinical and research purposes. One limitation of IT delivery is that drugs are rapidly lost from the middle ear by a number of processes, so that prolonged delivery of drug is technically difficult. In the present study, the delivery characteristics of a poloxamer hydrogel formulation containing dexamethasone (dex) were evaluated. The gel is liquid at room temperature, allowing IT injection, but transitions to a gel at body temperature, providing a prolonged residence time in the middle ear. A 50-μl volume of control or dex-containing gel (dex-gel) was injected through the tympanic membrane of guinea pigs. Cochlear function was assessed with cochlear action potential and acoustic emission thresholds measured immediately, 6 or 24 h after IT gel injection. After 6- or 24-hour treatment with dex-gel, perilymph drug gradients along the cochlea were assessed by taking samples sequentially from the apex, and endolymph was sampled from the basal turn. Control gel injections caused small changes in sound field calibrations and functional measures for low-frequency stimuli, consistent with an induced conductive loss. Within 24 h, responses returned to normal. Twenty-four hours after dex-gel injection, low-frequency changes remained as the dex-gel was retained better in the middle ear, but there was no indication of high-frequency loss. While perilymph sample data showed that dex gradients were substantially lower than after single injections of dex solution, quantitative analysis of this result suggests that some dex may have entered the perilymph through the thin bone in the apical region of the cochlea. Endolymph levels of dex remained lower than those in the perilymph. This study confirms that a poloxamer hydrogel-based dex formulation provides an effective method for a prolonged delivery, providing a more uniform distribution of drug in the inner ear.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21178339      PMCID: PMC3023000          DOI: 10.1159/000322504

Source DB:  PubMed          Journal:  Audiol Neurootol        ISSN: 1420-3030            Impact factor:   1.854


  32 in total

1.  Intratympanic dexamethasone and hyaluronic acid in patients with low-frequency and Ménière's-associated sudden sensorineural hearing loss.

Authors:  Oksana A Selivanova; Haralampos Gouveris; Anja Victor; Ronald G Amedee; Wolf Mann
Journal:  Otol Neurotol       Date:  2005-09       Impact factor: 2.311

2.  Quantitative interpretation of corticosteroid pharmacokinetics in inner fluids using computer simulations.

Authors:  Stefan K R Plontke; Alec N Salt
Journal:  Hear Res       Date:  2003-08       Impact factor: 3.208

3.  Novel slow- and fast-type drug release round-window microimplants for local drug application to the cochlea: an experimental study in guinea pigs.

Authors:  Wolfgang Arnold; Pascal Senn; Michael Hennig; Christiane Michaelis; Kerstin Deingruber; Renate Scheler; Hans-Joachim Steinhoff; Frits Riphagen; Kerstin Lamm
Journal:  Audiol Neurootol       Date:  2004-12-07       Impact factor: 1.854

4.  Hyaluronic acid hydrogel sustains the delivery of dexamethasone across the round window membrane.

Authors:  Robert C Borden; James E Saunders; Wayne E Berryhill; Greg A Krempl; David M Thompson; Lurdes Queimado
Journal:  Audiol Neurootol       Date:  2010-05-01       Impact factor: 1.854

5.  Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents.

Authors:  S S Chandrasekhar; R Y Rubinstein; J A Kwartler; M Gatz; P E Connelly; E Huang; S Baredes
Journal:  Otolaryngol Head Neck Surg       Date:  2000-04       Impact factor: 3.497

6.  Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application.

Authors:  L S Parnes; A H Sun; D J Freeman
Journal:  Laryngoscope       Date:  1999-07       Impact factor: 3.325

Review 7.  Ultrastructure of the middle ear mucosa.

Authors:  E Hentzer
Journal:  Acta Otolaryngol Suppl       Date:  1984

8.  Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss.

Authors:  Brian D Herr; Sam J Marzo
Journal:  Otolaryngol Head Neck Surg       Date:  2005-04       Impact factor: 3.497

Review 9.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

10.  Intratympanic dexamethasone with hyaluronic acid in the treatment of idiopathic sudden sensorineural hearing loss after failure of intravenous steroid and vasoactive therapy.

Authors:  Haralampos Gouveris; Oksana Selivanova; Wolf Mann
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-04-29       Impact factor: 2.503

View more
  30 in total

Review 1.  [Intracochlear drug delivery in combination with cochlear implants : Current aspects].

Authors:  S K Plontke; G Götze; T Rahne; A Liebau
Journal:  HNO       Date:  2016-11       Impact factor: 1.284

2.  Hearing Changes After Intratympanically Applied Steroids for Primary Therapy of Sudden Hearing Loss: A Meta-analysis Using Mathematical Simulations of Drug Delivery Protocols.

Authors:  Arne Liebau; Olivia Pogorzelski; Alec N Salt; Stefan K Plontke
Journal:  Otol Neurotol       Date:  2017-01       Impact factor: 2.311

3.  Dexamethasone and Dexamethasone Phosphate Entry into Perilymph Compared for Middle Ear Applications in Guinea Pigs.

Authors:  Alec N Salt; Jared J Hartsock; Fabrice Piu; Jennifer Hou
Journal:  Audiol Neurootol       Date:  2018-11-29       Impact factor: 1.854

4.  A Polymer-Based Extended Release System for Stable, Long-term Intracochlear Drug Delivery.

Authors:  Erik Pierstorff; Shanshan Chen; Maria Paola Chaparro; John M Cortez; Yen-Jung Chen; Su Young Ryu; Sherry M Tsai; Marc M Baum; Wan Wan Yang; Federico Kalinec; Thomas Smith; Stacey Ludwig; William H Slattery
Journal:  Otol Neurotol       Date:  2018-10       Impact factor: 2.311

5.  Controlled release dexamethasone implants in the round window niche for salvage treatment of idiopathic sudden sensorineural hearing loss.

Authors:  Stefan K Plontke; Alexander Glien; Torsten Rahne; Karsten Mäder; Alec N Salt
Journal:  Otol Neurotol       Date:  2014-08       Impact factor: 2.311

6.  A novel chitosan-hydrogel-based nanoparticle delivery system for local inner ear application.

Authors:  Shayanne A Lajud; Danish A Nagda; Peter Qiao; Nobuaki Tanaka; Alyssa Civantos; Rende Gu; Zhiliang Cheng; Andrew Tsourkas; Bert W O'Malley; Daqing Li
Journal:  Otol Neurotol       Date:  2015-02       Impact factor: 2.311

Review 7.  Communication pathways to and from the inner ear and their contributions to drug delivery.

Authors:  Alec N Salt; Keiko Hirose
Journal:  Hear Res       Date:  2017-12-19       Impact factor: 3.208

Review 8.  Delivery of therapeutics to the inner ear: The challenge of the blood-labyrinth barrier.

Authors:  Sophie Nyberg; N Joan Abbott; Xiaorui Shi; Peter S Steyger; Alain Dabdoub
Journal:  Sci Transl Med       Date:  2019-03-06       Impact factor: 17.956

9.  Assessment of PLGA-PEG-PLGA copolymer hydrogel for sustained drug delivery in the ear.

Authors:  Liang Feng; Jonette A Ward; S Kevin Li; Gaurav Tolia; Jinsong Hao; Daniel I Choo
Journal:  Curr Drug Deliv       Date:  2014       Impact factor: 2.565

10.  Perilymph pharmacokinetics of markers and dexamethasone applied and sampled at the lateral semi-circular canal.

Authors:  Alec N Salt; Jared J Hartsock; Ruth M Gill; Fabrice Piu; Stefan K Plontke
Journal:  J Assoc Res Otolaryngol       Date:  2012-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.